Flagship explainer

How Aquestive Therapeutics, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$44.5M · 100%Cost of revenue$18.6M · 42%Gross profit$26M · 58%Operating income−$71.1M · −160%Income before tax−$83.8M · −188%Income tax$0 · 0%Net income−$83.8M · −188%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$44.5M100%
Cost of revenue$18.6M42%
$26M58%
−$71.1M−160%
Income before tax−$83.8M−188%
Income tax$00%
−$83.8M−188%
Source: · event Dec 31, 2025 · retrieved Oct 20, 2026 · annual-row source set
Embed this chart

View the full Aquestive Therapeutics, Inc. analysis at Buy Like Buffett